More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
How can healthcare balance the pros and cons consumers see when they think about all the data being collected on them?
Well, the data is out there. I think there is a sense of the public trust having been violated and at the same time everybody acknowledges—I’ve got a lot of friends, especially younger generation, like “Yeah, they collect it and I don’t care. I have Alexa and I have Google in my home, and I know they’re collecting data on me and I don’t care.”
So, is healthcare data really any different? Or is the fact that we’re using social data that we can get on a patient to improve the care that we’re delivering, is that a bad thing? Or is that a good thing? That’s the kind of question that should be raised and debated, but in general, one of the guiding principles there is beneficence, and the good intention behind having that data in order to render better care is certainly noble.
So, at the end of the day, in healthcare, I think we win the ethical discussion and we are certainly in a better position than say the big industry tech giants that are using it for profit.
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More